Commentary

Redesign needed for Alzheimer’s screening programs

Publish date: September 16, 2013

 

Dr. Caselli is a professor of neurology and associate director and clinical core director of the Alzheimer’s Disease Center at the Mayo Clinic in Scottsdale, Ariz. He has no relevant financial disclosures.

Pages

Recommended Reading

Glucose, insulin measures unrelated to AD pathology
MDedge Internal Medicine
Aerobic exercise boosts brain power in mild cognitive impairment
MDedge Internal Medicine
Learning genetic risk for Alzheimer’s may not be so distressing
MDedge Internal Medicine
Higher glucose linked to increased dementia risk
MDedge Internal Medicine
New drug matched donepezil’s efficacy in mild to moderate Alzheimer’s
MDedge Internal Medicine
Alzheimer’s biomarkers have limited use in diagnosing frontotemporal dementia
MDedge Internal Medicine
Studies speak volumes about brain changes and cognition in women
MDedge Internal Medicine
Caregiver support program decreases dementia emergency visits
MDedge Internal Medicine
High-dose, high-potency statins reduced dementia risk
MDedge Internal Medicine
Diagnosing Alzheimer’s: The eyes may have it
MDedge Internal Medicine